Product Name: Pasireotide
CAS No: 396091-73-9
Purity: 95%
Molar Mass: 1047.21
Chemical Formula: C58H66N10O9
Synonyms: SOM230
Storage: Store at -20℃
Sequence: Cyclo[{4-(NH2-C2H4-NH-CO-O-)Pro}-Phg-{D-Trp}-K-{Tyr(4-Bzl)}-F]
Target: somatostatin receptors
Application: Pasireotide (CAS: 396091-73-9) is a synthetic cyclohexapeptide analog of somatostatin used in the treatment of Cushing’s disease, a condition characterized by excessive cortisol production due to pituitary adenomas. It functions by binding to somatostatin receptors, particularly subtype 1, 2, 3, and 5 (SST1, SST2, SST3, and SST5), which are overexpressed in corticotroph adenomas. Pasireotide inhibits the secretion of adrenocorticotropic hormone (ACTH) from pituitary adenomas, thereby reducing cortisol production by the adrenal glands. This leads to the normalization of cortisol levels and alleviation of symptoms associated with Cushing’s disease, such as weight gain, hypertension, and glucose intolerance. In pharmaceutical chemistry, pasireotide’s targeted binding to somatostatin receptors represents a significant advancement in the management of Cushing’s disease, offering a specific and effective therapeutic option for patients with this rare endocrine disorder. Its application underscores its importance in endocrinology and improving hormonal balance in individuals with Cushing’s disease. Additionally, ongoing research explores pasireotide’s potential in other neuroendocrine disorders and its role in combination therapies, highlighting its versatility in endocrine therapeutics.
